Asthma Drugs Market to Reach $47.6 Billion by 2035

Asthma drugs market was valued at $27.5 billion in 2025 and is projected to reach $47.6 billion by 2035, growing at a CAGR of 5.7% during the forecast period (2026-2035). The asthma drugs market is fundamentally driven by the sustained increase in disease prevalence and the growing number of patients requiring long-term pharmacological management. According to the World Health Organization, asthma affected approximately 262 million people globally, highlighting a significant and persistent patient base requiring continuous treatment. In the United States, the Centers for Disease Control and Prevention reports that nearly 26.8 million individuals currently live with asthma, representing about 8.2% of the population. This high prevalence directly translates into recurring demand for maintenance therapies such as inhaled corticosteroids and bronchodilators. A substantial proportion of patients experience periodic exacerbations, further reinforcing the need for consistent medication use and prescription renewals. Increasing diagnosis rates across both adult and pediatric populations are expanding the treated population base. Public health surveillance also indicates ongoing healthcare utilization, including physician visits and hospitalizations linked to asthma, supporting continuous drug consumption. The chronic nature of the condition necessitates lifelong management, ensuring stable and predictable revenue streams for pharmaceutical manufacturers.

Browse the full report description of “Asthma Drugs Market Size, Share & Trends Analysis Report by Drug Class (Bronchodilators, Anti-Inflammatory Drugs, Monoclonal Antibodies, and Combination Drugs), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), Forecast Period (2026–2035)” at https://www.omrglobal.com/industry-reports/asthma-drugs-market

Innovation Leaders Transforming the Asthma Drugs Market

The key players in the asthma drugs market include GlaxoSmithKline plc, AstraZeneca plc, Novartis AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., among others. These companies are advancing innovation in asthma therapeutics through the development of targeted biologic drugs, improved inhalation delivery systems, and optimized combination therapies, enabling effective long-term disease management and reduction in exacerbation rates while supporting the growing demand for precise, patient-centric respiratory care solutions.

• In March 2026, Zydus Lifesciences has introduced Aerolife Mini, a portable and foldable spacer designed to improve the effectiveness of inhaler-based treatments. The device helps deliver medication more efficiently to the lungs by reducing common inhaler usage errors. It addresses a major issue where many patients use inhalers incorrectly, leading to reduced treatment benefits.

• In December 2025, GlaxoSmithKline plc secured approval for depemokimab (Exdensur) for the treatment of severe asthma, offering a twice-yearly dosing regimen that enhances patient adherence and long-term disease management.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Drug Class
  • By Distribution Channel
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape - GlaxoSmithKline plc, AstraZeneca plc, Novartis AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Asthma Drugs Market Report Segment

By Drug Class

• Bronchodilators
• Anti-Inflammatory Drugs
• Monoclonal Antibodies
• Combination Drugs

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Asthma Drugs Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/asthma-drugs-market